{"filing":{"accession_number":"0000105770-26-000080","cik":"0000105770","ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"wst-20260531.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/wst-20260531.htm"},"events":[{"id":7656,"run_id":6730,"accession_number":"0000105770-26-000080","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Michel Lagarde was appointed as President and Chief Executive Officer effective August 31, 2026, and appointed to the Board of Directors, replacing retiring CEO Eric M. Green. The filing also discloses compensatory arrangements for Mr. Lagarde as part of this executive succession event.","company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":2935,"accession_number":"0000105770-26-000080","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Michel Lagarde as President and Chief Executive Officer effective August 31, 2026, replacing retiring CEO Eric M. Green. While the disclosure also covers Mr. Green's departure and detailed compensatory arrangements for Mr. Lagarde, the principal disclosed action is the appointment of a new CEO and board member. This is a material executive succession event for a large-cap pharmaceutical services company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:10:50.382204+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2936,"accession_number":"0000105770-26-000080","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure announces Mr. Lagarde's appointment as President and Chief Executive Officer and appointment to the Board, effective as of a specified start date. This is a material executive appointment at the C-suite level, as the CEO role is fundamental to investor assessment of company leadership and governance. The press release attached as Exhibit 99.1 documents this appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:10:50.382204+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2935,"accession_number":"0000105770-26-000080","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Michel Lagarde as President and Chief Executive Officer effective August 31, 2026, replacing retiring CEO Eric M. Green. While the disclosure also covers Mr. Green's departure and detailed compensatory arrangements for Mr. Lagarde, the principal disclosed action is the appointment of a new CEO and board member. This is a material executive succession event for a large-cap pharmaceutical services company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:10:50.382204+00:00","company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","filing_date":"2026-06-01"},{"id":2936,"accession_number":"0000105770-26-000080","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure announces Mr. Lagarde's appointment as President and Chief Executive Officer and appointment to the Board, effective as of a specified start date. This is a material executive appointment at the C-suite level, as the CEO role is fundamental to investor assessment of company leadership and governance. The press release attached as Exhibit 99.1 documents this appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:10:50.382204+00:00","company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","filing_date":"2026-06-01"}]}